February 24, 2024
You are here:  Home  >  Banking & Finance  >  Current Article

Arcutis share up after earnings report; company reports mounting losses but progress toward FDA approval


Westlake-Village based Arcutis Biotherapeutics continued to see rising losses in both the fourth quarter and full year of 2021, though the biotech company’s stock rose in the days following its Feb. 22 earnings release. Arcutis, a pre-revenue biotech company focusing on treating skin diseases, had a net loss of $71.3 million in the fourth quarter…


    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.